Details for Patent: 11,667,673
✉ Email this page to a colleague
Which drugs does patent 11,667,673 protect, and when does it expire?
Patent 11,667,673 protects TIBSOVO and is included in one NDA.
This patent has eighty-five patent family members in forty countries.
Drugs Protected by US Patent 11,667,673
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Servier | TIBSOVO | ivosidenib | TABLET;ORAL | 211192-001 | Jul 20, 2018 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | A METHOD OF TREATING A CANCER CHARACTERIZED BY AN IDH1 MUTATION WHEREIN THE CANCER IS RELAPSED OR REFRACTORY MYELODYSPLASTIC SYNDROMES | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 11,667,673
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| European Patent Office | 2804851 | ⤷ Sign Up | 301243 | Netherlands | ⤷ Sign Up |
| European Patent Office | 2804851 | ⤷ Sign Up | CA 2023 00025 | Denmark | ⤷ Sign Up |
| European Patent Office | 2804851 | ⤷ Sign Up | LUC00315 | Luxembourg | ⤷ Sign Up |
| European Patent Office | 2804851 | ⤷ Sign Up | PA2023529 | Lithuania | ⤷ Sign Up |
| European Patent Office | 2804851 | ⤷ Sign Up | 30/2023 | Austria | ⤷ Sign Up |
| European Patent Office | 2804851 | ⤷ Sign Up | 2023C/534 | Belgium | ⤷ Sign Up |
| European Patent Office | 2804851 | ⤷ Sign Up | 122023000051 | Germany | ⤷ Sign Up |
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
